Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
The amount, in billions of dollars, that Johnson & Johnson invested in research and development in 2021—a 21% increase over its previous all-time-high investment in 2020.
The number of procedures performed by the Monarch® platform, Johnson & Johnson’s first-of-its-kind robotic bronchoscopy technology, in 2021.
Circular image
Quote icon (top)

Research and development isn’t just the foundation of growth for our company—it’s the engine driving scientific progress in creating a healthier world. Johnson & Johnson has made an investment in innovation every year since 1886. And in doing so, every year we have taken on the responsibility of defining what we think healthcare can accomplish next. Forward-looking investments made years or even decades ago were the seeds for successful innovations that flowered across all our segments in 2021.

Quote icon (bottom)
Robert Wood Johnson, former chairman from 1932 to 1963 and a member of the Company’s founding family, crafted Our Credo himself in 1943, just before Johnson & Johnson became a publicly traded company. This was long before anyone ever heard the term “corporate social responsibility.” Our Credo is more than just a moral compass. We believe it’s a recipe for business success. The fact that Johnson & Johnson is one of only a handful of companies that have flourished through more than a century of change is proof of that.
This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue